Redmile Group LLC Sells 9,700 Shares of LivaNova PLC $LIVN

Redmile Group LLC lessened its position in shares of LivaNova PLC (NASDAQ:LIVN) by 8.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,354 shares of the company’s stock after selling 9,700 shares during the quarter. LivaNova comprises 0.5% of Redmile Group LLC’s portfolio, making the stock its 26th biggest holding. Redmile Group LLC owned approximately 0.20% of LivaNova worth $6,887,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Hantz Financial Services Inc. boosted its position in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after acquiring an additional 267 shares during the last quarter. State of Wyoming purchased a new position in shares of LivaNova in the second quarter valued at $31,000. Quarry LP bought a new stake in LivaNova in the third quarter worth $36,000. EverSource Wealth Advisors LLC raised its stake in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares in the last quarter. Finally, Covestor Ltd lifted its position in LivaNova by 108.6% during the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the sale, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. This trade represents a 19.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on LIVN shares. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Freedom Capital upgraded shares of LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Barclays increased their price target on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. KeyCorp lifted their price target on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Finally, Mizuho boosted their price objective on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.38.

LivaNova Stock Up 1.9%

NASDAQ LIVN opened at $82.09 on Wednesday. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. LivaNova PLC has a 52 week low of $41.01 and a 52 week high of $85.27. The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of 42.10 and a beta of 0.86. The company has a fifty day moving average of $78.66 and a two-hundred day moving average of $69.83.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. The firm had revenue of $362.26 million during the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, analysts predict that LivaNova PLC will post 3.73 earnings per share for the current year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.